Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety of Talquetamab and to determine the
recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab
(Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the
recommended Phase 2 dose(s) (RP2Ds) (Part 2 [Dose Expansion]).